---
title: UK pharma media reputation tracker – October 2026
canonical_url: https://www.omniscan.ai/benchmarks/uk-pharma-2026-10
type: dataset
publisher: Omniscan
sector: Pharma in the UK
period: October 2026
coverage_start: '2026-10-01'
coverage_end: '2026-10-31'
date_published: '2026-11-03'
last_updated: '2026-11-03'
organisations: 10
articles_analysed: 1122
mentions: 934
data_download: https://www.omniscan.ai/benchmarks/uk-pharma-2026-10/data.json
summary: AstraZeneca had the highest average monthly share of coverage (31.2%) among
  10 companies in UK earned media from 1 October 2026 to 31 October 2026, ahead of
  GSK (23.3%) and Eli Lilly (13.7%).
---

# UK pharma media reputation tracker: October 2026 (1 October 2026–31 October 2026)

> AstraZeneca had the highest average monthly share of coverage (31.2%) among 10 companies in UK earned media from 1 October 2026 to 31 October 2026, ahead of GSK (23.3%) and Eli Lilly (13.7%). AstraZeneca had the most favourable net tone (+62). Omniscan analysed 1,122 articles containing 934 mentions of the companies tracked.

Interactive version: https://www.omniscan.ai/benchmarks/uk-pharma-2026-10

## Pharma in the UK ranking by share of coverage, October 2026

| Rank | Organisation | Average monthly share of coverage | Mentions | Positive | Neutral | Negative | Net tone |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | AstraZeneca | 31.2% | 291 | 65% | 33% | 2% | +62 |
| 2 | GSK | 23.3% | 218 | 43% | 48% | 9% | +34 |
| 3 | Eli Lilly | 13.7% | 128 | 30% | 57% | 13% | +18 |
| 4 | Novo Nordisk | 12.7% | 119 | 11% | 76% | 13% | −2 |
| 5 | Pfizer | 4.0% | 37 | 24% | 65% | 11% | +14 |
| 6 | MSD | 3.4% | 32 | 47% | 44% | 9% | +38 |
| 7 | Roche | 3.3% | 31 | 35% | 52% | 13% | +23 |
| 8 | Novartis | 3.2% | 30 | 27% | 73% | 0% | +27 |
| 9 | Moderna | 2.8% | 26 | 69% | 23% | 8% | +62 |
| 10 | Sanofi | 2.4% | 22 | 41% | 59% | 0% | +41 |

## Companies in detail

### AstraZeneca

**Results, pipeline investment and partnerships define AstraZeneca’s October coverage**

AstraZeneca ranked 1st of 10 by average monthly share of coverage (31.2%) in the Pharma in the UK benchmark for October 2026, with 291 mentions and a net tone of +62.

AstraZeneca reported record quarterly revenue of $16.2 billion and a 23% rise in third-quarter net profit, supported by cancer medicines, alongside a restructuring programme targeting $1.5 billion in annual savings for pipeline reinvestment. It ranked first with 291 mentions and a 31.2% share of tracked-company mentions. Financial results and pipeline led the subject mix with 113 mentions, followed by clinical trials and research with 56, M&A and licensing with 48, and leadership and strategy with 45. Business Standard also reported AstraZeneca’s agreement with insitro, including a $40 million upfront payment and potential milestones of approximately $1.46 billion, to develop treatments for MASH and cardiomyopathies. Its research agenda included plans with Daiichi Sankyo and Summit Therapeutics to evaluate Datroway with ivonescimab across several tumour types, beginning with a phase 3 trial in first-line triple-negative breast cancer. Further coverage reported that chief executive Pascal Soriot was exploring potential work on cancer vaccines, supported by AstraZeneca’s recent mRNA research.

Key messages:

- AstraZeneca accounted for 31.2% of tracked-company mentions and ranked first among the 10 tracked companies in October 2026.
- Coverage concentrated on Financial Results & Pipeline and Clinical Trials & Research.
- The benchmark captured 291 AstraZeneca mentions in October 2026.
- Third-quarter profit growth and the savings plan — France 24

Leading themes:

- Financial Results & Pipeline: 38.8% of AstraZeneca's coverage (theme index 1.5, net tone +63)
- Clinical Trials & Research: 19.2% of AstraZeneca's coverage (theme index 1.08, net tone +63)
- M&A & Licensing: 16.5% of AstraZeneca's coverage (theme index 1.83, net tone +67)

Notable positive coverage:

- 16 October 2026, theglobeandmail.com: [AstraZeneca (AZN) Receives a Buy from UBS](https://www.theglobeandmail.com/investing/markets/stocks/AZN-N/pressreleases/8091111/astrazeneca-azn-receives-a-buy-from-ubs/). UBS reiterated a Buy rating on AstraZeneca with a 15,200p price target, while Barclays also maintained a Buy and Deutsche Bank retained a Hold. The article notes AstraZeneca's latest quarterly revenue rose year on year, while net profit was slightly lower.
- 30 October 2026, france24.com: [Drugs giant AstraZeneca reveals higher profits, savings plan](https://www.france24.com/en/live-news/20261030-drugs-giant-astrazeneca-reveals-higher-profits-savings-plan-1). AstraZeneca reported a 23% rise in third-quarter net profit to $3.12 billion and record quarterly revenue of $16.2 billion, supported by cancer medicines. It also announced a restructuring programme targeting $1.5 billion in annual savings for reinvestment in its pipeline, while saying there would be job losses but no net reduction in employment.
- 30 October 2026, lse.co.uk: [FTSE 100 movers: AstraZeneca surges on results; NatWest slides](https://www.lse.co.uk/news/ftse-100-movers-astrazeneca-surges-on-results-natwest-slides-qd9uo97npzpqv3l.html). AstraZeneca reported 7% total revenue growth for the first nine months, driven by double-digit growth in oncology, R&I and rare disease. It also announced a $1.5bn savings plan, while loss of exclusivity for Farxiga and Brilinta created headwinds.

Notable negative coverage:

- 24 October 2026, pharmaphorum.com: [ESMO26: Neoadjuvant Enhertu fails in early breast cancer](https://pharmaphorum.com/news/esmo26-neoadjuvant-enhertu-fails-early-breast-cancer). AstraZeneca and Daiichi Sankyo's Enhertu produced low pathological complete-response rates in the investigator-led TALENT trial in early-stage HR-positive, HER2-low breast cancer. The findings contrast with Enhertu's established benefit in advanced disease and may inform future curative-intent combination or sequencing studies.
- 12 October 2026, lse.co.uk: [AstraZeneca HPP trial results miss statistical significance](https://www.lse.co.uk/news/astrazeneca-hpp-trial-results-miss-statistical-significance-nqfhs4a3a84nazq.html). AstraZeneca said its phase-three Hickory trial of efzimfotase alfa in hypophosphatasia showed numerical improvement in walking distance but missed statistical significance. The company attributed the result partly to better-than-expected placebo performance.
- 12 October 2026, ad-hoc-news.de: [AstraZeneca reports 17.05-meter HICKORY result: stock after-hours at EUR 142.20](https://www.ad-hoc-news.de/boerse/news/nachboerse/astrazeneca-reports-17-05-meter-hickory-result-stock-after-hours-at-eur-142-20/70304509). AstraZeneca reported that its Phase III HICKORY trial of efzimfotase alfa showed a numerical 17.05-metre improvement over placebo in the six-minute walk test at week 25. However, the study's primary endpoint did not achieve statistical significance.

- [AstraZeneca deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10?entity=astrazeneca&view=deep-dive)
- [AstraZeneca PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10/reports/astrazeneca.pdf)

### GSK

**Vaccine weakness overshadows GSK’s earnings beat**

GSK ranked 2nd of 10 by average monthly share of coverage (23.3%) in the Pharma in the UK benchmark for October 2026, with 218 mentions and a net tone of +34.

GSK’s third-quarter results beat sales and core-profit expectations, but weaker Shingrix and Arexvy sales accompanied a sharp fall in its shares. The company ranked second with 218 mentions and a 23.3% share of tracked-company mentions. Financial results and pipeline dominated the subject mix with 114 mentions, followed by clinical trials and research with 40, M&A and licensing with 24, and leadership and strategy with 23. Reuters also reported that GSK and Hansoh Pharmaceutical’s ris-rez delayed osteosarcoma progression versus chemotherapy in a late-stage Chinese study. Other developments included a broader discovery collaboration with Chai Discovery after successful wet-lab evaluations and plans for up to 1,217 job cuts in Belgium. Together, the coverage connected immediate pressure on vaccines and restructuring costs with growth in specialty medicines and investment in oncology and late-stage research.

Key messages:

- GSK accounted for 23.3% of tracked-company mentions and ranked second among ten companies in October 2026.
- Coverage concentrated on Financial Results & Pipeline and Clinical Trials & Research.
- The benchmark captured 218 company mentions in October 2026.
- GSK’s earnings beat was overshadowed by falling vaccine sales — Evening Standard

Leading themes:

- Financial Results & Pipeline: 52.3% of GSK's coverage (theme index 2.26, net tone +4)
- Clinical Trials & Research: 18.3% of GSK's coverage (theme index 1, net tone +90)
- M&A & Licensing: 11.0% of GSK's coverage (theme index 0.96, net tone +63)

Notable positive coverage:

- 1 October 2026, bioworld.com: [GSK selects siRNA candidate from Wave Life Sciences collaboration](https://www.bioworld.com/articles/734415-gsk-selects-sirna-candidate-from-wave-life-sciences-collaboration). GSK has selected a hepatology siRNA candidate from its research collaboration with Wave Life Sciences for development.
- 6 October 2026, firstwordpharma.com: [GSK's long-acting Cabenuva scores win in unsuppressed HIV](https://firstwordpharma.com/story/8170708). GSK reported that ViiV's phase IIIb CROWN study found Cabenuva superior to daily oral antiretroviral therapy for viral suppression at six months in patients with unsuppressed HIV. Full data will be presented at a scientific meeting and shared with regulators.
- 19 October 2026, pharmaphorum.com: [Data reveal is promising for GSK's lung cancer drug ris-rez](https://pharmaphorum.com/news/data-reveal-promising-gsks-lung-cancer-drug-ris-rez). GSK reported promising phase 1b international trial data for risvutatug rezetecan in extensive-stage small-cell lung cancer, selecting an 8 mg/kg dose for its ongoing phase 3 trial. The B7-H3 antibody-drug conjugate was licensed from Hansoh Pharma in 2023 and showed a 61% overall response rate at the selected dose.

Notable negative coverage:

- 29 October 2026, lse.co.uk: [London's FTSE 100 rises as Shell boosts energy stocks](https://www.lse.co.uk/news/londons-ftse-100-rises-as-shell-boosts-energy-stocks-tcgd3m4wgljchm1.html). GSK's disappointing results contributed to a further decline in London-listed pharmaceutical shares. Haleon's separate consumer-health forecast cut also weighed on the sector, though Haleon is not part of GSK.
- 28 October 2026, independent.co.uk: [Eyes turn to US Fed call as markets 'tolerate' UK Budget](https://www.independent.co.uk/news/business/budget-eyes-fed-b3075130.html). GSK’s third-quarter earnings and sales beat forecasts, but its shares fell 4.8% after investors were unsettled by a below-consensus contribution from the vaccines division. The company was among the FTSE 100’s largest fallers.
- 28 October 2026, reuters.com: [London's FTSE 100 bogged down by GSK, Unilever; budget, Fed in focus](https://www.reuters.com/world/uk/londons-ftse-100-bogged-down-by-gsk-unilever-budget-fed-focus-2026-10-28/). GSK was among the leading FTSE 100 fallers following its quarterly results, contributing to a 0.3% decline in the index. The wider market was cautious ahead of the UK budget and a US Federal Reserve decision.

- [GSK deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10?entity=gsk&view=deep-dive)
- [GSK PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10/reports/gsk.pdf)

### Eli Lilly

**Foundayo backing and Mounjaro scrutiny shape Lilly’s October profile**

Eli Lilly ranked 3rd of 10 by average monthly share of coverage (13.7%) in the Pharma in the UK benchmark for October 2026, with 128 mentions and a net tone of +18.

Reuters reported that an EMA committee recommended Eli Lilly’s oral obesity and diabetes drug Foundayo after its UK launch in August. Third-quarter reporting showed 39% revenue growth, led by $16.1bn in combined Mounjaro and Zepbound sales, while Lilly raised its 2026 revenue outlook and reduced its adjusted profit forecast because of acquisition-related charges. Eli Lilly ranked third with 128 mentions and a 13.7% share of tracked-company mentions. Medicines safety, supply and patient use dominated the subject mix with 64 mentions, ahead of NHS access and pricing with 18, drug approvals and launches with 15, and financial results and pipeline with 14. Coverage of Mounjaro included MPs’ warnings that its NHS rollout was too slow and risked entrenching unequal access, alongside reporting on misuse, illicit sales, side effects and scrutiny of Lilly’s obesity-awareness advertising. Further company developments included Phase III data in which retatrutide outperformed Ozempic and the discontinuation of the FHD-909 cancer programme after insufficient Phase I efficacy.

Key messages:

- Eli Lilly accounted for 13.7% of tracked-company mentions and ranked third among ten companies in October 2026.
- Coverage concentrated on Medicines Safety, Supply & Patient Use and NHS Access & Pricing.
- The benchmark captured 128 company mentions in October 2026.
- Foundayo wins European regulatory backing — Reuters

Leading themes:

- Medicines Safety, Supply & Patient Use: 50.0% of Eli Lilly's coverage (theme index 5.84, net tone −2)
- NHS Access & Pricing: 14.1% of Eli Lilly's coverage (theme index 2.91, net tone −6)
- Drug Approvals & Launches: 11.7% of Eli Lilly's coverage (theme index 3.05, net tone +100)

Notable positive coverage:

- 16 October 2026, qz.com: [Eli Lilly's weight-loss pill won backing from a European drug regulator panel](https://qz.com/lilly-foundayo-weight-loss-pill-eu-panel-backing-101626). Eli Lilly's oral obesity and type 2 diabetes treatment Foundayo (orforglipron) received a positive opinion from an EMA committee, pending a final European Commission decision. The pill was authorised by the MHRA and launched privately in the UK in August at £100-£120 a month.
- 16 October 2026, reuters.com: [Eli Lilly's weight-loss pill wins EU drug regulator's backing](https://www.reuters.com/legal/litigation/eli-lillys-weight-loss-pill-wins-backing-europe-2026-10-16/). Eli Lilly's oral obesity and diabetes drug Foundayo received a positive recommendation from the EMA, following its UK launch in August. The article compares its uptake and administration advantages with Novo Nordisk's oral Wegovy, which is also available in the UK.
- 16 October 2026, pharmaceutical-technology.com: [Lilly's Foundayo wins EMA panel backing for obesity and type 2 diabetes](https://www.pharmaceutical-technology.com/news/lillys-foundayo-wins-ema-panel-backing-for-obesity-and-type-2-diabetes/). An EMA panel backed Eli Lilly's Foundayo for obesity and type 2 diabetes, positioning it to compete in the UK and European oral GLP-1 market with Novo Nordisk's Wegovy and Rybelsus. The article reports favourable trial and sales performance for Lilly's wider tirzepatide franchise while noting Novo's first-mover advantage in oral obesity pills.

Notable negative coverage:

- 30 October 2026, thesun.co.uk: [I lied to get weight loss jabs... I was so ill I thought I'd die](https://www.thesun.co.uk/fabulous/32782501/lied-ozempic-weight-loss-jabs-side-effects/). Danielle Mason describes obtaining Eli Lilly’s Mounjaro privately by misrepresenting her weight and experiencing severe gastrointestinal symptoms, anxiety and panic attacks after increasing her dose. An NHS GP warns that use outside licensed eligibility criteria, incomplete medical disclosures and potential drug interactions can be dangerous.
- 30 October 2026, theguardian.com: [Everyone is thin and we're not allowed to say so: the toxic legacy of body positivity](https://www.theguardian.com/lifeandstyle/2026/oct/30/body-positivity-ozempic-thinness). The article examines the cultural backlash against renewed thinness ideals in the GLP-1 era, citing Eli Lilly’s sponsorship of Vogue World Milano. Eating-disorder advocates criticise the association of the fashion event with Lilly, manufacturer of Mounjaro and Zepbound, while the company says it aims to shift discussion of weight from aesthetics to health.
- 15 October 2026, bbc.co.uk: [£2m fake weight-loss pens found in 'filthy' Birmingham hub](https://www.bbc.co.uk/news/articles/c6y8ln122592o). The MHRA seized more than 12,000 counterfeit weight-loss pens, including fake tirzepatide and retatrutide products, from a Birmingham industrial unit. The regulator warned that the unlicensed products may contain harmful or contaminated substances.

- [Eli Lilly deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10?entity=elililly&view=deep-dive)
- [Eli Lilly PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10/reports/elililly.pdf)

### Novo Nordisk

**Wegovy demand meets scrutiny over safety, access and approval**

Novo Nordisk ranked 4th of 10 by average monthly share of coverage (12.7%) in the Pharma in the UK benchmark for October 2026, with 119 mentions and a net tone of −2.

Novo Nordisk’s October coverage centred on medicines safety, supply and patient use, with 57 articles addressing issues including clinical oversight, counterfeit products and patient experiences. One article reported that more than one million Wegovy tablet packs had been sold during the first eight weeks of the UK launch. The company recorded 119 mentions, representing 12.7% of tracked-company mentions and placing it fourth in the supplied competitive ranking. Safety reporting included alleged links between Ozempic and Wegovy and the optic-nerve condition NAION, which Novo Nordisk disputes. Approval coverage included India’s regulator requesting local bioequivalence, clinical-trial and formulation data before further consideration of oral Wegovy. Financial and pipeline reporting included Citi’s price-target cut, citing limited expected margin growth from higher R&D spending, while research coverage addressed Wegovy’s reported reduction of liver fat and Novo Nordisk’s planned presentation of 26 abstracts at ObesityWeek 2026.

Key messages:

- Novo Nordisk accounted for 12.7% of tracked-company mentions and ranked fourth among ten companies in October 2026.
- Coverage concentrated on Medicines Safety, Supply & Patient Use and Drug Approvals & Launches.
- The benchmark captured 119 company mentions in October 2026.
- The Sun reported that more than one million Wegovy pill packs had been sold since the UK launch.

Leading themes:

- Medicines Safety, Supply & Patient Use: 47.9% of Novo Nordisk's coverage (theme index 5.14, net tone −16)
- Drug Approvals & Launches: 11.8% of Novo Nordisk's coverage (theme index 3, net tone 0)
- Financial Results & Pipeline: 10.9% of Novo Nordisk's coverage (theme index 0.33, net tone +8)

Notable positive coverage:

- 1 October 2026, thesun.co.uk: [Half a million people 'taking Wegovy pill' since UK launch](https://www.thesun.co.uk/health/40542945/half-million-people-wegovy-pill-study-weight-loss-continues/). Novo Nordisk said it sold more than one million packs of Wegovy tablets in the first eight weeks following their UK launch, equating to an estimated 500,000 users. The article highlights strong demand alongside warnings about counterfeit products and the need for clinical oversight.
- 30 October 2026, ft.com: [GLP-1 pioneer Lotte Bjerre Knudsen: 'The food industry has to listen'](https://www.ft.com/content/c920d800-a22e-4f4e-a592-5fc361b0955e). A profile of former Novo Nordisk scientific adviser Lotte Bjerre Knudsen examines her pioneering work on GLP-1 medicines, including Ozempic and Wegovy, and their effects on obesity, appetite and food consumption. It notes growing UK use of weight-loss medicines and discusses patient-reported benefits alongside known side effects.
- 22 October 2026, independent.co.uk: [How to lose weight in your fifties - the healthiest thing you can do in your lifetime](https://www.independent.co.uk/health-and-fitness/lose-weight-midlife-over-50-healthy-b3070960.html). A midlife weight-loss feature cites evidence that semaglutide, the active ingredient in Wegovy and Ozempic, reduced major cardiovascular events in the SELECT trial. It advises readers considering weight-loss medication to consult a GP and use registered pharmacies.

Notable negative coverage:

- 30 October 2026, mirror.co.uk: [Doctor's Omeprazole, Wegovy, and Metformin 'higher risk' warning](https://www.mirror.co.uk/news/health/doctor-issues-higher-risk-warning-37825765). A doctor warned that GLP-1 weight-loss medicines, including Wegovy and Zepbound, may be associated with nutritional deficiencies and rare Wernicke encephalopathy, particularly where nausea, vomiting or reduced food intake occur. The article also notes NHS advice on recognising and addressing thiamine deficiency.
- 23 October 2026, independent.co.uk: [Nurse struck off after falsifying patients' records to get herself weight loss jabs](https://www.independent.co.uk/news/uk/home-news/weight-loss-glp1-ozempic-nurse-sarah-didymus-b3072150.html). A Cornwall nurse was struck off after falsifying patient records and prescriptions to obtain NHS-subsidised Ozempic, semaglutide and Trulicity for herself. The case concerns fraudulent acquisition and misuse of weight-loss and diabetes medicines rather than conduct by their manufacturers.
- 21 October 2026, inews.co.uk: [Wegovy was supposed to make me perfect. Three days in I regretted everything](https://inews.co.uk/opinion/wegovy-make-perfect-three-days-regretted-everything-4838621). A columnist describes severe nausea, weakness and appetite loss after taking an excessively high dose of Wegovy obtained outside legitimate prescribing channels, despite not meeting eligibility criteria. The article also reflects on body-image pressures and non-medical use of weight-loss injections.

- [Novo Nordisk deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10?entity=novonordisk&view=deep-dive)
- [Novo Nordisk PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10/reports/novonordisk.pdf)

### Pfizer

**Vaccine trials and myeloma evidence define Pfizer’s October profile**

Pfizer ranked 5th of 10 by average monthly share of coverage (4.0%) in the Pharma in the UK benchmark for October 2026, with 37 mentions and a net tone of +14.

Pfizer’s October coverage was led by clinical research, including forthcoming Phase 3 VALOR data for its Lyme disease vaccine candidate with Valneva and recruitment for the Pfizer-sponsored BEATRIX maternal Group B Streptococcus vaccine trial. Pfizer ranked fifth with 37 mentions and a 4% share of tracked-company mentions. Clinical Trials & Research was the largest subject area with 10 mentions, while NHS Access & Pricing, Regulation & MHRA, and Vaccines & Public Health each recorded five. BEATRIX coverage included recruitment across 10 UK hospitals and the first European participant entering the study in Shropshire. Separately, elranatamab met its progression-free-survival endpoint in the MagnetisMM-32 myeloma trial, prompting examination of prospective NICE appraisal, NHS capacity and managed access. Medicines-safety reporting also covered claims linking long-term Depo-Provera use to meningiomas, alongside Scottish guidance for patient warnings and prescription reviews.

Key messages:

- Pfizer accounted for 4% of tracked-company mentions and ranked fifth among ten companies in October 2026.
- Clinical Trials & Research led coverage; NHS Access & Pricing, Regulation & MHRA, and Vaccines & Public Health were joint second.
- The benchmark captured 37 company mentions in October 2026.
- VALOR Lyme disease vaccine data presentation — Ad Hoc News

Leading themes:

- Clinical Trials & Research: 27.0% of Pfizer's coverage (theme index 1.51, net tone +70)
- NHS Access & Pricing: 13.5% of Pfizer's coverage (theme index 2.33, net tone −20)
- Vaccines & Public Health: 13.5% of Pfizer's coverage (theme index 10.1, net tone +20)

Notable positive coverage:

- 8 October 2026, pharmatimes.com: [Group B Strep mums urge women to join vaccine trial](https://pharmatimes.com/news/group-b-strep-mums-urge-women-to-join-vaccine-trial/). Pfizer is sponsoring the NIHR-supported BEATRIX phase 3 UK maternal vaccine trial for group B streptococcus. Families affected by neonatal GBS are encouraging pregnant women to participate in the study.
- 5 October 2026, nationalhealthexecutive.com: [Pregnant women invited to join groundbreaking global trial for GBS vaccine](https://www.nationalhealthexecutive.com/articles/pregnant-women-invited-join-groundbreaking-global-trial-gbs-vaccine). Pfizer-sponsored BEATRIX is recruiting pregnant women at 10 UK hospitals for a Phase III trial of a maternal vaccine against group B streptococcus. The NIHR-supported study will assess whether vaccination can protect newborns from severe GBS infection.
- 2 October 2026, oxfordmail.co.uk: [Oxford mothers invited to join world-first vaccine trial](https://www.oxfordmail.co.uk/news/26597936.oxford-vaccine-trial-aims-prevent-newborn-infections/). Pfizer is sponsoring the BEATRIX phase 3 trial of an investigational maternal Group B streptococcus vaccine across 10 UK sites, including Oxford's John Radcliffe Hospital. The study will assess whether maternal vaccination protects infants from GBS infection.

Notable negative coverage:

- 14 October 2026, dailyrecord.co.uk: [Depo jag victim left with 'brain slipping down spine' after symptoms dismissed](https://www.dailyrecord.co.uk/news/scottish-news/my-brain-slipping-down-spine-37765817). A Scottish woman attributes multiple meningiomas and serious neurological harm to long-term use of Pfizer's Depo-Provera contraceptive injection, while pursuing compensation alongside other claimants. The article reports new Scottish GP warnings and prescription-review guidance concerning the tumour risk, alongside calls for a UK public inquiry.
- 7 October 2026, dailyrecord.co.uk: ["I found out my brain tumours were linked to my contraceptive jab on Google"](https://www.dailyrecord.co.uk/news/scottish-news/i-found-out-brain-tumours-37739862). A Scottish woman says long-term use of Pfizer-manufactured Depo-Provera was linked to her brain tumours, amid expanding UK group litigation and calls for a public inquiry. Scottish health officials have instructed GPs to warn patients about tumour risks and review prescriptions regularly.

- [Pfizer deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10?entity=pfizer&view=deep-dive)
- [Pfizer PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10/reports/pfizer.pdf)

### MSD

**Melanoma vaccine trial anchors MSD’s October profile**

MSD ranked 6th of 10 by average monthly share of coverage (3.4%) in the Pharma in the UK benchmark for October 2026, with 32 mentions and a net tone of +38.

The BBC led coverage of phase III results showing that MSD’s Keytruda combined with Moderna’s personalised mRNA vaccine intismeran reduced the risk of melanoma recurrence or death by 42%. MSD recorded 32 mentions, representing 3.4% of tracked-company mentions and sixth place among the cohort. Clinical trials and research dominated the subject mix with 18 mentions, ahead of M&A and licensing with four, while financial results and pipeline and patents and intellectual property each accounted for three. Patent reporting centred on a Dutch court order barring subcutaneous Keytruda in eight European countries, although MSD disputed the ruling and cited the cancellation of the related UK patent. Pharmaphorum also reported NICE guidance enabling NHS England access to Keytruda for locally advanced cervical cancer and early-stage head and neck cancer. Wider sector coverage referenced the melanoma results, compared AstraZeneca’s bladder-cancer regimen with an established Keytruda-Padcev approach and measured GSK’s oncology business against Keytruda.

Key messages:

- MSD accounted for 3.4% of tracked-company mentions and ranked sixth among the 10-company cohort in October 2026.
- Coverage concentrated on Clinical Trials & Research and M&A & Licensing.
- The benchmark captured 32 company mentions in October 2026.
- Personalised melanoma vaccine trial results combining Keytruda and intismeran — BBC

Leading themes:

- Clinical Trials & Research: 56.3% of MSD's coverage (theme index 3.32, net tone +78)
- M&A & Licensing: 12.5% of MSD's coverage (theme index 1.11, net tone 0)
- Patents & Intellectual Property: 9.4% of MSD's coverage (theme index 16.91, net tone −67)

Notable positive coverage:

- 23 October 2026, aol.co.uk: [First personalised cancer vaccine cuts risk of disease returning in major trial](https://www.aol.co.uk/articles/world-first-personalised-cancer-vaccine-074907000.html). A UK-involving phase-three melanoma trial found that MSD’s Keytruda combined with Moderna’s personalised mRNA cancer vaccine Intismeran reduced the risk of recurrence, death or disease spread versus immunotherapy alone. The companies are testing the approach in other cancers and may seek regulatory approval next year, although experts said longer follow-up is needed.
- 23 October 2026, bbc.co.uk: [First personalised cancer vaccine stops disease returning in major trial](https://www.bbc.co.uk/news/articles/cq0ld9g9e913o). A major melanoma trial involving UK patients found that MSD’s Keytruda combined with Moderna’s personalised mRNA vaccine Intismeran reduced the risk of recurrence or death by 42%. The companies are engaging regulators ahead of potential filings, while experts say longer follow-up is needed and future NHS use will depend on cost.
- 24 October 2026, newswire.lk: [A major step forward in cancer treatment? New vaccine delivers promising results](https://www.newswire.lk/2026/10/24/a-major-step-forward-in-cancer-treatment/). A personalised mRNA cancer-vaccine trial at Addenbrooke’s Hospital, used alongside MSD’s Keytruda, reported reduced risks of melanoma recurrence, death and spread versus Keytruda alone. The phase-three findings are not yet peer-reviewed and would require regulatory approval before potential NHS availability.

Notable negative coverage:

- 8 October 2026, biz.chosun.com: [Halozyme court win halts Keytruda SC in Europe, puts Alteogen royalties at risk - CHOSUNBIZ](https://biz.chosun.com/en/en-science/2026/10/08/ZUKZCXYYSNATBL37BL7SQWF22Y/?outputType=amp). A Dutch court barred MSD's Keytruda SC in eight European countries after finding infringement of Halozyme's drug-delivery patent. The report notes that the relevant UK patent was revoked and that MSD previously received a favourable UK outcome.
- 9 October 2026, juve-patent.com: [Halozyme takes the win over MSD’s cancer drug Keytruda in the Netherlands](https://www.juve-patent.com/cases/halozyme-takes-the-win-over-msds-cancer-drug-keytruda-in-the-netherlands/). The Hague District Court upheld Halozyme's patent and ordered MSD to stop marketing subcutaneous Keytruda in eight European countries, subject to potentially €50 million in penalties. The broader dispute includes pending UK nullity proceedings concerning the patent.

- [MSD deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10?entity=msd&view=deep-dive)
- [MSD PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10/reports/msd.pdf)

### Roche

**Roche’s October profile spans access, oncology and licensing**

Roche ranked 7th of 10 by average monthly share of coverage (3.3%) in the Pharma in the UK benchmark for October 2026, with 31 mentions and a net tone of +23.

Reporting highlighted Roche’s agreement with Hansoh Pharma, potentially worth more than $15 billion, and its development of a pill intended for advanced lung cancer. Roche recorded 31 mentions, representing 3.3% of tracked-company mentions and placing it seventh in the cohort. M&A and licensing was the leading subject with seven mentions, followed by financial results and pipeline and clinical trials and research with five each. NHS access and pricing accounted for four mentions, including NICE’s final draft guidance against routine NHS use of the Itovebi combination for advanced breast cancer over cost-effectiveness and evidence uncertainties. Patent coverage centred on Genentech’s settlement with Biocon, permitting the planned UK and EU launch of the Perjeta biosimilar Pebrilzo in the first quarter of 2027. As context, wider sector articles referred to Genentech’s existing collaboration with OMass Therapeutics and Roche’s place in obesity-drug research, but did not report developments led by Roche.

Key messages:

- Roche accounted for 3.3% of tracked-company mentions and ranked seventh among ten companies in October 2026.
- Coverage was led by M&A & Licensing, followed jointly by Financial Results & Pipeline and Clinical Trials & Research.
- The benchmark captured 31 company mentions in October 2026.
- Hansoh Pharma struck a drug-development agreement with Roche potentially worth more than $15 billion — RAPS

Leading themes:

- M&A & Licensing: 22.6% of Roche's coverage (theme index 2.06, net tone +29)
- Financial Results & Pipeline: 16.1% of Roche's coverage (theme index 0.53, net tone +80)
- Clinical Trials & Research: 16.1% of Roche's coverage (theme index 0.88, net tone +40)

Notable positive coverage:

- 26 October 2026, morningstar.com: [Dow Jones Top Company Headlines at 3 AM ET: Roche Targets Emerging Oncology Market With New Lung-Cancer Drug | AstraZeneca ...](https://www.morningstar.com/news/dow-jones/20261026657/dow-jones-top-company-headlines-at-3-am-et-roche-targets-emerging-oncology-market-with-new-lung-cancer-drug-astrazeneca). Roche is developing a pill it expects could become a standard treatment for an advanced form of lung cancer. AstraZeneca is preparing regulatory filings for a portfolio of targeted oncology therapies.
- 19 October 2026, morningstar.com: [Dow Jones Top Company Headlines at 1 PM ET: Jamie Dimon's National-Security Pledge Finances $230 Billion in First Year | Quantinuum ...](https://www.morningstar.com/news/dow-jones/202610195509/dow-jones-top-company-headlines-at-1-pm-et-jamie-dimons-national-security-pledge-finances-230-billion-in-first-year-quantinuum). Roche has partnered with China’s Hansoh in a deal that could be worth more than $15 billion. Roche will take responsibility for the asset outside Greater China following early-stage clinical trials.
- 19 October 2026, morningstar.com: [Dow Jones Top Company Headlines at 11 AM ET: Jamie Dimon's National-Security Pledge Finances $230 Billion in First Year | Quantinuum ...](https://www.morningstar.com/news/dow-jones/202610194467/dow-jones-top-company-headlines-at-11-am-et-jamie-dimons-national-security-pledge-finances-230-billion-in-first-year-quantinuum). Roche has partnered with China’s Hansoh in a deal potentially worth more than $15 billion. Roche will take responsibility for the product outside Greater China following early-stage clinical trials.

Notable negative coverage:

- 15 October 2026, pharmaphorum.com: [Roche breast cancer drug Itovebi turned down by NICE](https://pharmaphorum.com/news/roche-breast-cancer-drug-itovebi-turned-down-nice). NICE has declined to recommend routine NHS use of Roche's Itovebi combination for a form of advanced breast cancer, citing cost-effectiveness and evidence uncertainties. Roche described the outcome as devastating for patients and called for reform of the UK medicines-value assessment system.
- 16 October 2026, genomeweb.com: [NICE Does Not Recommend Itovebi Regimen in Advanced Breast Cancer](https://www.genomeweb.com/business-news/reimbursement/gnw-itovebi-nice-nhs-uk-rejects-coverage-20261015/). NICE's final draft guidance does not recommend Roche's Itovebi-based breast-cancer regimen after Roche and NHS England failed to agree a cost-effective price. Roche called the decision devastating for eligible patients and criticised the UK's approach to valuing innovative combination medicines.

- [Roche deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10?entity=roche&view=deep-dive)
- [Roche PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10/reports/roche.pdf)

### Novartis

**Raised guidance and Abogen licensing defined Novartis’s October coverage**

Novartis ranked 8th of 10 by average monthly share of coverage (3.2%) in the Pharma in the UK benchmark for October 2026, with 30 mentions and a net tone of +27.

Novartis raised its full-year earnings guidance on sales growth and productivity gains, despite clinical-trial setbacks and declining Entresto sales, as reported by Morningstar. It ranked eighth with 30 mentions, representing 3.2% of tracked-company mentions. Financial results and pipeline led the subject mix with nine mentions, followed by clinical trials and research with five, M&A and licensing with four, and NHS access and pricing with three. PharmExec reported an exclusive worldwide licence and options agreement with Abogen covering its mRNA-encoded autoimmune-treatment candidate and other potential RNA programmes. CNBC valued the agreement at up to $7.8 billion, including upfront and potential milestone payments. TechTimes reported that Novartis could delay or bypass European state payers for investigational Sjögren’s treatment ianalumab in response to US most-favoured-nation pricing. UK developments included a regional healthcare-innovation partnership focused initially on cardiovascular disease and oncology, while Mondaq reported that the Patents Court upheld Novartis’s Entresto patent and supplementary protection certificate.

Key messages:

- Novartis accounted for 3.2% of tracked-company mentions and ranked eighth among ten companies in October 2026.
- Coverage concentrated on Financial Results & Pipeline and Clinical Trials & Research.
- The benchmark captured 30 company mentions in October 2026.
- Raised full-year earnings guidance despite trial setbacks — Morningstar

Leading themes:

- Financial Results & Pipeline: 30.0% of Novartis's coverage (theme index 1, net tone 0)
- Clinical Trials & Research: 16.7% of Novartis's coverage (theme index 0.91, net tone +40)
- M&A & Licensing: 13.3% of Novartis's coverage (theme index 1.18, net tone +25)

Notable positive coverage:

- 9 October 2026, labiotech.eu: [More options, better odds: the changing prostate cancer treatment landscape](https://www.labiotech.eu/in-depth/prostate-cancer-new-drugs/). The article reviews changing prostate-cancer treatments, including Novartis's Pluvicto expansion and UK research at the Royal Marsden and Institute of Cancer Research showing SBRT may offer safety advantages over surgery. It also covers competing radiopharmaceutical, hormonal and antibody-drug-conjugate programmes.
- 17 October 2026, wired-gov.net: [New strategic partnership to shape the future of health and care across Cheshire and Merseyside](https://www.wired-gov.net/wg/news.nsf/articles/new+strategic+partnership+to+shape+the+future+of+health+and+care+across+cheshire+and+merseyside+16102026122500?open). Novartis UK has signed a memorandum of understanding with Health Innovation North West Coast and NHS partners to improve the adoption of healthcare innovation in Cheshire and Merseyside. The collaboration will initially focus on cardiovascular disease and oncology, using regional data, research and service redesign to support more equitable patient access.
- 7 October 2026, mondaq.com: [UK Patents Court Reinforces The UK Threshold For Plausibility - Patent - United Kingdom](https://www.mondaq.com/uk/patent/1852054/uk-patents-court-reinforces-the-uk-threshold-for-plausibility). The UK Patents Court upheld Novartis's patent and supplementary protection certificate for Entresto, rejecting validity challenges brought by Accord Healthcare. The ruling clarifies the UK plausibility threshold for patents relying on experimental findings without full numerical data in the specification.

- [Novartis deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10?entity=novartis&view=deep-dive)
- [Novartis PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10/reports/novartis.pdf)

### Moderna

**Melanoma trial defines Moderna’s October profile**

Moderna ranked 9th of 10 by average monthly share of coverage (2.8%) in the Pharma in the UK benchmark for October 2026, with 26 mentions and a net tone of +62.

Coverage centred on Phase III results for Moderna and MSD’s personalised mRNA melanoma vaccine, intismeran, combined with Keytruda. The BBC and Independent reported a lower risk of recurrence or death than with Keytruda alone, while STAT quantified the reduction at 42% and noted potential applications in other tumour types. Moderna recorded 26 mentions and a 2.8% share of tracked-company mentions, ranking ninth. Clinical trials and research dominated with 17 mentions, followed by vaccines and public health with five; financial results and pipeline, and UK investment and manufacturing, each accounted for one. Pharmaceutical Technology separately reported how Moderna was applying Covid-era manufacturing lessons to its mRNA pipeline and outsourced production network, including its UK facility. Investor coverage included a 14% share-price rise amid expectations around a planned US public-private cancer-vaccine initiative, and a later 10% fall during a wider vaccine-stock sell-off. Wider UK clinical-trial reporting also said faster setup times supported Moderna’s Nova 301 norovirus-vaccine study, although it did not focus on a development at the company.

Key messages:

- Moderna accounted for 2.8% of tracked-company mentions and ranked ninth among ten companies in October 2026.
- Coverage concentrated on Clinical Trials & Research and Vaccines & Public Health.
- The benchmark captured 26 company mentions in October 2026.
- Phase III personalised melanoma-vaccine results — BBC

Leading themes:

- Clinical Trials & Research: 65.4% of Moderna's coverage (theme index 3.86, net tone +88)
- Vaccines & Public Health: 19.2% of Moderna's coverage (theme index 14.55, net tone +20)
- Financial Results & Pipeline: 3.8% of Moderna's coverage (theme index 0.13, net tone 0)

Notable positive coverage:

- 23 October 2026, bbc.com: [First personalised cancer vaccine cuts risk of disease returning in major trial](https://www.bbc.com/news/articles/cq0ld9g9e913o). A UK-linked melanoma trial involving patients at Addenbrooke's Hospital found that personalised mRNA vaccine Intismeran plus MSD's Keytruda reduced the risk of recurrence or death versus immunotherapy alone. MSD and Moderna said they are engaging regulators, while experts urged longer follow-up and noted the findings are not yet peer-reviewed.
- 24 October 2026, lbc.co.uk: [World-first personalised cancer jab cuts risk of melanoma returning or death by 42% in major trial](https://www.lbc.co.uk/article/world-first-personalised-cancer-jab-cuts-risk-of-melanoma-5HjdkMX_2/). A phase III trial involving UK and international patients found Moderna’s personalised mRNA melanoma vaccine intismeran plus MSD’s Keytruda reduced recurrence or death by 42% versus Keytruda alone. The experimental treatment is not yet available on the NHS and will require further approval and assessment.
- 23 October 2026, independent.co.uk: [World-first personalised cancer vaccine slashes risk of death and disease returning](https://www.independent.co.uk/news/uk/home-news/cancer-vaccine-melanoma-mrna-msd-moderna-b3072161.html). A phase-three trial including patients at Addenbrooke's Hospital in Cambridge found that Moderna and MSD's personalised mRNA cancer vaccine combined with Keytruda reduced melanoma recurrence or death versus Keytruda alone. The partners are also testing the approach in kidney, bladder and lung cancers.

Notable negative coverage:

- 16 October 2026, aol.co.uk: [Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady](https://www.aol.co.uk/articles/novavax-plunges-12-selloff-hits-164410000.html). Novavax shares fell sharply alongside Moderna as vaccine stocks sold off, while Pfizer was broadly flat. Sanofi, Novavax's licensing partner, is rolling out the Nuvaxovid Covid-19 vaccine in the UK, Germany and Canada, with Novavax's royalty prospects dependent on that commercialisation.

- [Moderna deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10?entity=moderna&view=deep-dive)
- [Moderna PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10/reports/moderna.pdf)

### Sanofi

**Partnerships and patient programmes shaped Sanofi’s October coverage**

Sanofi ranked 10th of 10 by average monthly share of coverage (2.4%) in the Pharma in the UK benchmark for October 2026, with 22 mentions and a net tone of +41.

Articles included Sanofi’s collaboration and licensing agreement with ScionxBio to develop long-acting mRNA therapies, with Sanofi responsible for later development, manufacturing and worldwide commercialisation. UCL reported that Sanofi was progressing a patent based on an award-winning wearable drug-delivery design, while Pharmafile covered its severe-asthma service project with University Hospitals Birmingham. Sanofi recorded 22 mentions, representing 2.4% of tracked-company mentions and placing it tenth in the cohort. Financial results and pipeline, and leadership and strategy, each accounted for four mentions, while clinical research and vaccines and public health each accounted for three. Patient-focused coverage included the Tackle Diabetes campaign with England rugby player Henry Slade, addressing understanding, early detection and stigma around type 1 diabetes. Other articles reported Sanofi’s renewed immunology partnership with Regeneron and its rollout of Novavax’s Nuvaxovid vaccine for the autumn season.

Key messages:

- Sanofi accounted for 2.4% of tracked-company mentions and ranked tenth among the 10 companies in October 2026.
- Coverage concentrated on Financial Results & Pipeline and Leadership & Strategy.
- The benchmark captured 22 company mentions in October 2026.
- ScionxBio and Sanofi’s long-acting mRNA collaboration — Manufacturing Chemist

Leading themes:

- Leadership & Strategy: 18.2% of Sanofi's coverage (theme index 2.24, net tone 0)
- Financial Results & Pipeline: 18.2% of Sanofi's coverage (theme index 0.6, net tone 0)
- Vaccines & Public Health: 13.6% of Sanofi's coverage (theme index 8.88, net tone +67)

Notable positive coverage:

- 21 October 2026, manufacturingchemist.com: [ScionxBio and Sanofi partner on long-acting mRNA therapies](https://www.manufacturingchemist.com/scionxbio-sanofi-partner-long-acting-mrna-therapies). UK-based ScionxBio has entered a collaboration and licensing agreement with Sanofi to develop long-acting mRNA therapeutics using its AI-driven TERA platform. Sanofi will lead later preclinical development, clinical development, manufacturing and worldwide commercialisation.
- 2 October 2026, firstwordpharma.com: [Friday Five: Sanofi and Regeneron (re)partner up in the face of Dupixent's patent cliff, AstraZeneca invests $2B in Summit, Lilly delivers more weight loss wins…and more](https://firstwordpharma.com/story/8152036). AstraZeneca made a $2 billion equity investment in Summit Therapeutics to support development of ivonescimab combinations, amid investor concerns about recent pipeline setbacks. The roundup also covers Sanofi's expanded Regeneron alliance, positive Eli Lilly obesity-trial data, and licensing activity by MSD and Novo Nordisk.
- 11 October 2026, pharmafile.com: [Excellence in Healthcare Partnership Awards - A Collaborative Working Project Between Sanofi and The University Hospital Birmingham Severe Asthma Team](https://pharmafile.com/features/excellence-in-healthcare-partnership-awards-a-collaborative-working-project-between-sanofi-and-the-university-hospital-birmingham-severe-asthma-team/). Sanofi and University Hospitals Birmingham won an award for a collaborative severe-asthma service project that funded and implemented a biologics administrator role. The project increased biologic-treatment initiations, reduced waiting times and secured ongoing NHS funding for the post.

- [Sanofi deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10?entity=sanofi&view=deep-dive)
- [Sanofi PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10/reports/sanofi.pdf)

## Methodology

- **Share of coverage**: an organisation's mentions divided by all mentions of the organisations tracked in the same sector that month, in UK earned media. It is the central measure of media visibility in Omniscan benchmarks. "Average monthly share" is the mean of the monthly shares across the reporting period.
- **Mention**: one article that covers an organisation, classified as positive, neutral or negative in tone. Articles are deduplicated, and an organisation's own websites and passing sponsorship name-checks are excluded, so only earned media counts.
- **Net tone**: positive mentions minus negative mentions, as a percentage of all mentions (range −100 to +100).
- **Themes**: every article is assigned to one of the sector's editorial themes. A theme index above 1 means the organisation is covered on that theme more than its peers are; below 1 means less.
- **Calculation**: every figure is computed directly from the classified articles; narrative summaries are checked against those figures.
- **Sources**: UK national and international, trade and specialist, regional and local, and aggregator and syndication media coverage, including sponsored and contributed material.

## Other Pharma in the UK editions

- [UK pharma media reputation tracker – 2026 year to date](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd.md)
- [UK pharma media reputation tracker – H1 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1.md)
- [UK pharma media reputation tracker – July 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07.md)
- [UK pharma media reputation tracker – August 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08.md)
- [UK pharma media reputation tracker – September 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-09.md)
- [All Omniscan media benchmarks](https://www.omniscan.ai/benchmarks.md)

## How to cite

Omniscan, "UK pharma media reputation tracker", October 2026 (1 October 2026–31 October 2026), published 3 November 2026. https://www.omniscan.ai/benchmarks/uk-pharma-2026-10
